Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Johannes Meiler"'
Autor:
Ulrich-Frank Pape, Stefan Kasper, Johannes Meiler, Marianne Sinn, Arndt Vogel, Lothar Müller, Oswald Burkhard, Karel Caca, Steffen Heeg, Petra Büchner-Steudel, Victor Rodriguez-Laval, Anja A Kühl, Ruza Arsenic, Holger Jansen, Peter Treasure, Nalân Utku
Publikováno v:
Cancers, Vol 12, Iss 11, p 3149 (2020)
CAP7.1 is a novel topoisomerase II inhibitor, converted to active etoposide via carboxylesterase 2 (CES2), with signals of efficacy in treatment-refractory solid tumours. In a Phase II trial, 27 patients with advanced biliary tract cancers (BTC) were
Externí odkaz:
https://doaj.org/article/d6f1af887cc748eabce8407f4407d5c8
Autor:
J. Sahlmann, Ulrike Söling, Corinne Vannier, Norbert Marschner, Leonora Houet, Pauline Wimberger, C Brucker, Manfred Welslau, Oliver J. Stoetzer, Johannes Meiler, Steffen Dörfel, Karin Potthoff
Publikováno v:
Cancer Research. 80:P5-11
Background: The pivotal PALOMA trials investigated the combination of the cyclin-dependent kinase 4/6 inhibitor palbociclib with letrozole as first-line treatment or with fulvestrant after prior endocrine therapy in patients with advanced HR+/HER2- b
Autor:
Viktor Grünwald, Thomas Hilser, Johannes Meiler, Peter J. Goebell, Philipp Ivanyi, Arne Strauss, Arndt Hartmann, Jens Bedke, Lothar Bergmann
Publikováno v:
Oncology research and treatment. 45(5)
Introduction: Inhibition of neo-angiogenesis is a cornerstone of medical treatment in metastatic renal cell carcinoma (mRCC). While 1st line therapies were previously dominated by inhibitors of the vascular endothelial growth factor axis, 2nd line op
Autor:
Matthias Egger, Stephan Probst, Jörg Trojan, Alexander Reichart, Dirk M Behringer, Salah-Eddin Al-Batran, Volker Rethwisch, Michael Pohl, Gerald Illerhaus, Jan Stoehlmacher, Jörg Weniger, Daniel Pink, Wael Hozaeel, Rolf Mahlberg, Georg Martin Haag, Severin Daum, Carmen Löhr, Wolff Schmiegel, Michael Heike, G. Schuch, Timo Gaiser, Flot Aio Investigators, Thorsten Oliver Goetze, Helga Bernhard, Sebastian Belle, Nils Homann, Johannes Meiler, Hans-Georg Kopp, Nicole Prasnikar, Christian Teschendorf, Andreas Block, Michael Schenk, Volker Heinemann, Markus Moehler, Stefan Kasper, Claudia Pauligk, Kim Barbara Luley, Ralf Hofheinz, Harald Schmalenberg, Michael Kneba, Frank Kullmann, Wolf O. Bechstein, Jörg T. Hartmann, Uwe M. Martens, Martin Schuler, U. Lindig, Fuat Oduncu, Peter C. Thuss-Patience, Thomas Kraus, Gunnar Folprecht, Frank Mayer, Michael Koenigsmann, Elke Jäger, Wolfgang Fischbach, Stefan Mönig, Ludwig Fischer von Weikersthal, Martina Güntner, Karsten Schulmann
Publikováno v:
The Lancet. 393:1948-1957
Background Docetaxel-based chemotherapy is effective in metastatic gastric and gastro-oesophageal junction adenocarcinoma. This study reports on the safety and efficacy of the docetaxel-based triplet FLOT (fluorouracil plus leucovorin, oxaliplatin an
Autor:
Johannes Meiler, Victor Rodriguez-Laval, Steffen Heeg, Anja A. Kühl, Ruza Arsenic, Ulrich-Frank Pape, Karel Caca, Stefan Kasper, Holger Jansen, Arndt Vogel, Oswald Burkhard, Petra Büchner-Steudel, Marianne Sinn, Peter Treasure, Nalân Utku, Lothar Müller
Publikováno v:
Cancers
Volume 12
Issue 11
Cancers, Vol 12, Iss 3149, p 3149 (2020)
Volume 12
Issue 11
Cancers, Vol 12, Iss 3149, p 3149 (2020)
CAP7.1 is a novel topoisomerase II inhibitor, converted to active etoposide via carboxylesterase 2 (CES2), with signals of efficacy in treatment-refractory solid tumours. In a Phase II trial, 27 patients with advanced biliary tract cancers (BTC) were
Autor:
Isabel Virchow, Karl Worm, Tanja Trarbach, Winfried Berger, Saskia Ting, Brigitte Schumacher, Tilman Steinmetz, Thomas Höhler, Johannes Meiler, Martin Schuler, Peter Reimer, Gabriele Linden, Stefan Kasper, Thomas Herold, Marcel Wiesweg, Kurt Werner Schmid, Peter Markus, Heike Knipp, Alexander Dechêne, Karina Kostbade, Andreas Paul, Henning Reis
Background The multicenter, single-arm, phase II study CEBIFOX evaluated the efficacy of a biweekly cetuximab administration in combination with FOLFOX6 as first-line therapy in KRAS (exon 2) wild-type (wt) metastatic colorectal cancer (mCRC). Patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5696b5ebc448e4c4fa8e944cdfb072ca
https://www.ncbi.nlm.nih.gov/pubmed/32737003
https://www.ncbi.nlm.nih.gov/pubmed/32737003
Autor:
Lothar Müller, M-R. Rafiyan, Lothar Bergmann, Anne Flörcken, Peter Staib, M. Metz, T. Kretz, E. Hellmis, P. Schütt, Stefanie Zschäbitz, Martin Schostak, Anja Lorch, Philipp Ivanyi, Thomas Steiner, Viktor Grünwald, Manfred P. Wirth, Axel Hinke, C. Darr, M. Mänz, Johannes Meiler
Publikováno v:
Annals of Oncology. 32:S700
Autor:
Henning Reis, Marcel Wiesweg, Martin Schuler, Nikoleta Savvidou, Kurt Werner Schmid, Johannes Meiler, Thomas Hager, Charlotte Skiba, Filiz Oezkan, Martin Stuschke, Karl Worm, Clemens Aigner, Wilfried Eberhardt, Saskia Ting, Stefan Kasper, Hilmar Kühl, Jörg Hense, Kaid Darwiche, Dirk Theegarten, Thomas Herold, Daniel C. Christoph, Stefan Welter
Publikováno v:
Journal of Thoracic Oncology. 12:54-64
OA embargo Objectives Chromosomal rearrangements involving ROS1 define a rare entity of lung adenocarcinomas with exquisite sensitivity to molecularly targeted therapy. We report clinical outcomes and genomic findings of patients with ROS1-positive l
Autor:
Arndt Vogel, Arno Schad, M.P. Lutz, Peter C. Thuss-Patience, Markus Moehler, Florian Lordick, Sylvie Lorenzen, E. Van Cutsem, S.-E. Al-Batran, Maria Alsina, Baruch Brenner, Julia Slotta-Huspenina, Annett Maderer, Wolfgang Eisterer, Kersten Borchert, Lothar Mueller, Richard Greil, Johannes Meiler, R.D. Hofheinz, Thomas J. Ettrich
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 31(2)
Background Palliative chemotherapy of advanced oesophageal squamous cell cancer (ESCC) consists of cisplatin/5-fluorouracil (CF) to target epidermal growth factor receptor (EGFR) with panitumumab (P); chemotherapy enhanced overall survival (OS) in ad
Autor:
Ulrich-Frank Pape, Oswald Burkhard, Nalan Utku, Karel Caca, Steffen Heeg, Ruza Arsenic, Lothar Mueller, Marianne Sinn, Anya A Kühl, Johannes Meiler, Holger Jansen, Arndt Vogel, Victor Rodriguez Laval, Stefan Kasper
264 Background: The novel drug EDO-S7.1 (CAP7.1) is converted to active etoposide by CES allowing administration of higher doses, reducing resistance, and permitting treatment of advanced tumors. Methods: The primary objective was to compare disease
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9884cad576c01a7ea15c3ebf4032cc29